Literature DB >> 1519983

UK experience in neonatal extracorporeal membrane oxygenation.

G A Pearson1, D J Field, R K Firmin, A S Sosnowski.   

Abstract

Extracorporeal membrane oxygenation (ECMO) is a life support technique capable of supporting pulmonary, cardiac, or cardiopulmonary function. It has proved most successful in neonatal respiratory failure. We report the initial UK experience with a survival rate of 80% in 15 neonates (gestations 36-41 weeks, birth weights 2690-3990 g) whose condition exceeded American criteria for ECMO treatment for a prolonged period before referral. Ages at referral varied from 11 to 240 hours and the duration of bypass required varied from 30 to 240 hours respectively.

Entities:  

Mesh:

Year:  1992        PMID: 1519983      PMCID: PMC1590433          DOI: 10.1136/adc.67.7_spec_no.822

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  11 in total

Review 1.  Extracorporeal life support for cardiopulmonary failure.

Authors:  R H Bartlett
Journal:  Curr Probl Surg       Date:  1990-10       Impact factor: 1.909

Review 2.  Extracorporeal membrane oxygenation.

Authors:  A W Sosnowski; S J Bonser; D J Field; T R Graham; R K Firmin
Journal:  BMJ       Date:  1990-08-11

3.  Extracorporeal membrane oxygenation.

Authors:  S J Rose
Journal:  BMJ       Date:  1990-09-22

Review 4.  Neonatal extracorporeal membrane oxygenation: how not to assess novel technologies.

Authors:  S J Elliott
Journal:  Lancet       Date:  1991-02-23       Impact factor: 79.321

5.  Low-frequency positive-pressure ventilation with extracorporeal CO2 removal in severe acute respiratory failure.

Authors:  L Gattinoni; A Pesenti; D Mascheroni; R Marcolin; R Fumagalli; F Rossi; G Iapichino; G Romagnoli; L Uziel; A Agostoni
Journal:  JAMA       Date:  1986-08-15       Impact factor: 56.272

6.  Morbidity for survivors of extracorporeal membrane oxygenation: neurodevelopmental outcome at 1 year of age.

Authors:  P Glass; M Miller; B Short
Journal:  Pediatrics       Date:  1989-01       Impact factor: 7.124

7.  Extracorporeal membrane oxygenation (ECMO) in neonatal respiratory failure. 100 cases.

Authors:  R H Bartlett; A B Gazzaniga; J Toomasian; A G Coran; D Roloff; R Rucker; A G Corwin
Journal:  Ann Surg       Date:  1986-09       Impact factor: 12.969

8.  National experience with extracorporeal membrane oxygenation for newborn respiratory failure. Data from 715 cases.

Authors:  J M Toomasian; S M Snedecor; R G Cornell; R E Cilley; R H Bartlett
Journal:  ASAIO Trans       Date:  1988 Apr-Jun

9.  Extracorporeal circulation in neonatal respiratory failure: a prospective randomized study.

Authors:  R H Bartlett; D W Roloff; R G Cornell; A F Andrews; P W Dillon; J B Zwischenberger
Journal:  Pediatrics       Date:  1985-10       Impact factor: 7.124

10.  Extracorporeal membrane oxygenation for newborn respiratory failure: forty-five cases.

Authors:  R H Bartlett; A F Andrews; J M Toomasian; N J Haiduc; A B Gazzaniga
Journal:  Surgery       Date:  1982-08       Impact factor: 3.982

View more
  4 in total

1.  Extracorporeal life support in paediatrics.

Authors:  G A Pearson; J Grant; D Field; A Sosnowski; R K Firmin
Journal:  Arch Dis Child       Date:  1993-01       Impact factor: 3.791

2.  Pathological complications of non-survivors of newborn extracorporeal membrane oxygenation.

Authors:  M J Evans; P A McKeever; G A Pearson; D Field; R K Firmin
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1994-09       Impact factor: 5.747

3.  Role of ECMO in the treatment of respiratory syncytial virus bronchiolitis: a collaborative report.

Authors:  J Y Khan; S J Kerr; A Tometzki; L Tyszczuk; J West; A Sosnowski; D McCrae; C Skeoch; C Davis; R K Firmin
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1995-09       Impact factor: 5.747

Review 4.  Neurocognitive Outcome After Treatment With(out) ECMO for Neonatal Critical Respiratory or Cardiac Failure.

Authors:  Raisa M Schiller; Dick Tibboel
Journal:  Front Pediatr       Date:  2019-11-26       Impact factor: 3.418

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.